These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 9625435)

  • 1. Transcriptional down-regulation of c-myc expression in an erythroleukemic cell line, K562, and its doxorubicin-resistant variant by two topoisomerase II inhibitors, doxorubicin and amsacrine.
    Clary A; Larrue A; Pourquier P; Robert J
    Anticancer Drugs; 1998 Mar; 9(3):245-54. PubMed ID: 9625435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Down-regulation of bcr-abl and bcl-x(L) expression in a leukemia cell line and its doxorubicin-resistant variant by topoisomerase II inhibitors.
    Laroche-Clary A; Larrue A; Robert J
    Biochem Pharmacol; 2000 Dec; 60(12):1823-8. PubMed ID: 11108797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of amsacrine (m-AMSA) on bulk and gene-specific DNA damage and c-myc expression in MCF-7 breast tumor cells.
    Bunch RT; Povirk LF; Orr MS; Randolph JK; Fornari FA; Gewirtz DA
    Biochem Pharmacol; 1994 Jan; 47(2):317-29. PubMed ID: 8304976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA topoisomerase II inhibitor, etoposide, induces p21WAF1/CIP1 through down-regulation of c-Myc in K562 cells.
    Horiguchi-Yamada J; Fukumi S; Saito S; Nakayama R; Iwase S; Yamada H
    Anticancer Res; 2002; 22(6C):3827-32. PubMed ID: 12553001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Down-regulation of c-Myc and Max genes is associated to inhibition of protein phosphatase 2A in K562 human leukemia cells.
    Lerga A; Belandia B; Delgado MD; Cuadrado MA; Richard C; Ortiz JM; Martín-Perez J; León J
    Biochem Biophys Res Commun; 1995 Oct; 215(3):889-95. PubMed ID: 7488057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Doxorubicin-induced alterations of c-myc and c-jun gene expression in rat glioblastoma cells: role of c-jun in drug resistance and cell death.
    Pourquier P; Montaudon D; Huet S; Larrue A; Clary A; Robert J
    Biochem Pharmacol; 1998 Jun; 55(12):1963-71. PubMed ID: 9714316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced topoisomerase II activity in multidrug-resistant human non-small cell lung cancer cell lines.
    Eijdems EW; de Haas M; Timmerman AJ; Van der Schans GP; Kamst E; de Nooij J; Astaldi Ricotti GC; Borst P; Baas F
    Br J Cancer; 1995 Jan; 71(1):40-7. PubMed ID: 7819046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of bulk and c-myc P2 promoter-specific DNA damage by an anti-topoisomerase II agent salvicine is an early event leading to apoptosis in HL-60 cells.
    Meng L; Ding J
    FEBS Lett; 2001 Jul; 501(1):59-64. PubMed ID: 11457456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of cell cycle regulation and apoptosis triggering in determining the sensitivity of leukemic cells to topoisomerase I and II inhibitors.
    Dubrez L; Goldwasser F; Genne P; Pommier Y; Solary E
    Leukemia; 1995 Jun; 9(6):1013-24. PubMed ID: 7596166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC 833.
    Beketic-Oreskovic L; Durán GE; Chen KG; Dumontet C; Sikic BI
    J Natl Cancer Inst; 1995 Nov; 87(21):1593-602. PubMed ID: 7563202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of c-myc expression and c-Myc function in response to sustained DNA damage in MCF-7 breast tumor cells.
    Magnet KJ; Orr MS; Cleveland JL; Rodriguez-Galindo C; Yang H; Yang C; Di YM; Jain PT; Gewirtz DA
    Biochem Pharmacol; 2001 Sep; 62(5):593-602. PubMed ID: 11585056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HT1080/DR4: a P-glycoprotein-negative human fibrosarcoma cell line exhibiting resistance to topoisomerase II-reactive drugs despite the presence of a drug-sensitive topoisomerase II.
    Zwelling LA; Slovak ML; Doroshow JH; Hinds M; Chan D; Parker E; Mayes J; Sie KL; Meltzer PS; Trent JM
    J Natl Cancer Inst; 1990 Oct; 82(19):1553-61. PubMed ID: 1976136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selection of a subpopulation with fewer DNA topoisomerase II alpha gene copies in a doxorubicin-resistant cell line panel.
    Withoff S; Keith WN; Knol AJ; Coutts JC; Hoare SF; Mulder NH; de Vries EG
    Br J Cancer; 1996 Aug; 74(4):502-7. PubMed ID: 8761362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transfection of a human topoisomerase II alpha gene into etoposide-resistant human breast tumor cells sensitizes the cells to etoposide.
    Asano T; An T; Zwelling LA; Takano H; Fojo AT; Kleinerman ES
    Oncol Res; 1996; 8(3):101-10. PubMed ID: 8823806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A human small cell lung carcinoma cell line, resistant to 4'-(9-acridinylamino)-methanesulfon-m-anisidide and cross-resistant to camptothecin with a high level of topoisomerase I.
    Prost S; Riou G
    Biochem Pharmacol; 1994 Aug; 48(5):975-84. PubMed ID: 8093110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple patterns of resistance of human leukemia cell sublines to amsacrine analogues.
    Finlay GJ; Baguley BC; Snow K; Judd W
    J Natl Cancer Inst; 1990 Apr; 82(8):662-7. PubMed ID: 2157028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of differentiation and growth arrest associated with nascent (nonoligosomal) DNA fragmentation and reduced c-myc expression in MCF-7 human breast tumor cells after continuous exposure to a sublethal concentration of doxorubicin.
    Fornari FA; Jarvis WD; Grant S; Orr MS; Randolph JK; White FK; Mumaw VR; Lovings ET; Freeman RH; Gewirtz DA
    Cell Growth Differ; 1994 Jul; 5(7):723-33. PubMed ID: 7947387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In K562 leukemia cells treated with doxorubicin and hemin, a decrease in c-myc mRNA expression correlates with loss of self-renewal capability but not with erythroid differentiation.
    Toffoli G; Viel A; Bevilacqua C; Maestro R; Tumiotto L; Boiocchi M
    Leuk Res; 1989; 13(4):279-87. PubMed ID: 2654492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Altered topoisomerase I activity and recombination activating gene expression in a human leukemia cell line resistant to doxorubicin.
    Riou JF; Grondard L; Petitgenet O; Abitbol M; Lavelle F
    Biochem Pharmacol; 1993 Sep; 46(5):851-61. PubMed ID: 8396937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationships between DNA damage and growth inhibition induced by topoisomerase II-interfering drugs in doxorubicin-sensitive and -resistant rat glioblastoma cells.
    de Tinguy-Moreaud E; Pourquier P; Montaudon D; Robert J
    Anticancer Res; 1994; 14(1A):99-103. PubMed ID: 8166463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.